戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  hyperinsulinemic-euglycemic clamp and a 2-h hyperglycemic clamp.
2 n littermates (ZCL rats) before and during a hyperglycemic clamp.
3 (pot) or AIR(max), but requires conduct of a hyperglycemic clamp.
4 ons, after a 30-g oral glucose, and during a hyperglycemic clamp.
5 s (1stIR and 2ndIR) were assessed by using a hyperglycemic clamp.
6 /min) during euglycemia and after 6 hours of hyperglycemic clamp.
7 ynthesis and glucose turnover rates during a hyperglycemic clamp.
8 on during glucose tolerance tests as well as hyperglycemic clamps.
9  oral glucose challenge and hyperinsulinemic-hyperglycemic clamps.
10  an oral glucose tolerance test and two-step hyperglycemic clamp (100 and 300 mg/dL) followed by intr
11 normal-weight AA versus C peers during a 2-h hyperglycemic clamp (12.5 mmol/L) on two occasions: 1) i
12  sensitivity and insulin clearance and a 2-h hyperglycemic clamp (12.5 mmol/l) to assess first- and s
13             A subgroup (n=70) received a 2-h hyperglycemic clamp (+125 mg/dL), and first- and second-
14 fusion of either saline or NA, followed by a hyperglycemic clamp (200 mg/dl).
15 8 micromol x kg(-1) x min(-1)), and during a hyperglycemic clamp, a failure to suppress endogenous gl
16                         During the prolonged hyperglycemic clamp, a rise in leptin was observed durin
17   We measured insulin secretion during a 2-h hyperglycemic clamp and calculated the disposition index
18                                              Hyperglycemic clamp and ex vivo glucose-stimulated insul
19       We studied healthy individuals using a hyperglycemic clamp and GLP-1 infusion.
20   beta-Cell function was determined with the hyperglycemic clamp and morphometric analysis of pancrea
21 d-phase insulin responses to a 2-h 13 mmol/l hyperglycemic clamp and the insulin response to a subseq
22             Insulin secretory responses to a hyperglycemic clamp and to a superimposed arginine bolus
23 se-induced insulin secretion both in vivo in hyperglycemic clamps and ex vivo in isolated islets from
24                                 We performed hyperglycemic clamps and intravenous glucose tolerance t
25 ndirect calorimetry), insulin secretion (2-h hyperglycemic clamp), and body composition (dual-energy
26 se in ex vivo perifusion experiments, during hyperglycemic clamps, and following i.p. glucose challen
27  in the overnight fasting state and during a hyperglycemic clamp ( approximately 150 mg/dl) in 10 rec
28 history of diabetes) were exposed to 48 h of hyperglycemic clamping (approximately 12 mmol/l).
29                                              Hyperglycemic clamps (approximately 15 mmol/l) were done
30 dogs underwent a hyperinsulinemic (4x basal) hyperglycemic clamp (arterial blood glucose 146 +/- 2 mg
31 ges, glucose tolerance tests, euglycemic and hyperglycemic clamps, as well as isolated islet and peri
32                              A euinsulinemic hyperglycemic clamp at 5, 10, and 15 mmol/l glucose was
33 insulin release in response to i.v. glucose (hyperglycemic clamps at 250 or 350 mg/dl plasma glucose)
34 -cell function was measured with a nine-step hyperglycemic clamp before and 48 h and 14 days after th
35  as the ratio of the OGTT-betaCGS to the 2-h hyperglycemic clamp-betaCGS.
36 rst- and second-phase insulin secretion (2-h hyperglycemic clamp), body composition and abdominal adi
37 travenous glucose tolerance test (IVGTT) and hyperglycemic clamp characterized the insulinotropic eff
38 nd demonstrated higher insulin levels during hyperglycemic clamps compared to saline controls.
39                                        Under hyperglycemic clamp conditions the transgenic mice had g
40                                              Hyperglycemic clamps conducted at baseline, after 12 mon
41                                              Hyperglycemic clamps confirmed an increase in insulin se
42                   Insulin sensitivity during hyperglycemic clamp declined by ~30% and ~55% (both P <
43 tration curve during the first 12 min of the hyperglycemic clamp (DeltaC-pep[AUC]0-12) was inversely
44 rements, and hyperinsulinemic-euglycemic and hyperglycemic clamp experiments were performed in RLIP76
45 n and two women, BMI 32.6 +/- 0.6) underwent hyperglycemic clamping for 24 h with hourly determinatio
46            In the first experiment, during a hyperglycemic clamp, glucagon was infused at 0.4 ng/kg/m
47                                     During a hyperglycemic clamp, glucose production was suppressed a
48 went oral glucose tolerance tests (OGTT) and hyperglycemic clamp (HC) procedures, followed by arginin
49  euglycemia followed by a 60-min +5.5 mmol/L hyperglycemic clamp (HG).
50 travenous glucose tolerance test (IVGTT) and hyperglycemic clamp (HGC) in 17 nondiabetic subjects (14
51 1c [HbA1c] 7.8 +/- 1.1%) or hyperinsulinemic-hyperglycemic clamp (HH) (n = 10; 44 +/- 12 years, 8 fem
52 e reabsorption was measured with the stepped hyperglycemic clamp in 15 subjects with type 2 diabetes
53 glucose infusion rate/insulin (mg/kg/min) by hyperglycemic clamp in 50 adolescents with T1D (age 16.1
54 by applying mathematical modeling during the hyperglycemic clamp in 60 normal glucose tolerance (NGT)
55 ein for 150 min to create a hyperinsulinemic-hyperglycemic clamp in EX-Basal, EX-Sim, and sedentary d
56      In vivo studies using the IVGTT and the hyperglycemic clamp in Sprague Dawley rats demonstrate i
57 e clearance versus insulin levels during the hyperglycemic clamp in the two small groups showed both
58           Stable serum insulin levels during hyperglycemic clamping in patients with NIDDM in the pre
59 ensitivity and secretion were assessed using hyperglycemic clamps in adults and frequently sampled in
60 on GLP-1-stimulated insulin secretion during hyperglycemic clamps in nondiabetic Caucasian individual
61             We studied insulin secretion (by hyperglycemic clamp) in 3-, 9-, and 20-month-old chronic
62 sma C-peptide concentration curve during the hyperglycemic clamp increased by 22 +/- 4 and 23 +/- 4%
63 r change in plasma glucose levels during the hyperglycemic clamp, individuals with T1DM had significa
64                                   During the hyperglycemic clamp, lipid infusion enhanced the insulin
65                          During the 7 mmol/l hyperglycemic clamp, maintaining a high FFA flux resulte
66 se to glucose was assessed with a +125 mg/dl hyperglycemic clamp on day 3.
67 -1, we performed a five-step (1-h intervals) hyperglycemic clamp on seven heterozygous members (NM) a
68     Intravenous infusion of indinavir during hyperglycemic clamps on rats significantly suppressed th
69  intravenous glucose challenge followed by a hyperglycemic clamp protocol, during which the plasma-in
70 glucose turnover during fasting and during a hyperglycemic clamp.RESULTSExendin 9-39 increased fastin
71 he first (10-80 min) and second (90-160 min) hyperglycemic clamp steps increased by 3.8-fold and 1.9-
72 ), respectively, during the first and second hyperglycemic clamp steps.
73 meostasis by hyperinsulinemic-euglycemic and hyperglycemic clamp studies and energy expenditure by in
74                                           In hyperglycemic clamp studies of Wistar rats, CGP37157 inc
75 Dawley rats (n = 28) were subjected to a 4-h hyperglycemic clamp study (approximately 11 mmol/l).
76 rglycemia on incretin receptor expression, a hyperglycemic clamp study was performed for 96 h with re
77 and free fatty acid (FFA) turnover using the hyperglycemic clamp technique in combination with isotop
78 ealthy subjects (HS) was conducted using the hyperglycemic clamp technique together with duodenal nut
79  A subsample of 81 adolescents underwent the hyperglycemic clamp technique.
80 ciation measuring insulin sensitivity by the hyperglycemic clamp technique.
81   Insulin sensitivity was assessed using the hyperglycemic clamp technique.
82                  During the hyperinsulinemic-hyperglycemic clamp that followed either exercise or res
83 active such as during fasting, diabetes, and hyperglycemic clamp, the concentration of GR mRNA increa
84                                   During the hyperglycemic clamp, there was decreased suppression of
85 re challenged with the same hyperinsulinemic-hyperglycemic clamp to simulate identical postprandial-l
86               Insulin sensitivity during the hyperglycemic clamp was not affected by empagliflozin in
87 AM, n = 5; CHADN, n = 6), a hyperinsulinemic-hyperglycemic clamp was used to assess whether CHADN cou
88          A hyperinsulinemic-euglycemic and a hyperglycemic clamp were performed in 110 youths to quan
89                                              Hyperglycemic clamps were also performed in a rat model
90                     Insulin responses during hyperglycemic clamps were augmented by saturated but not
91 ucose infusion rates during hyperinsulinemic-hyperglycemic clamps were increased with GLUT4 overexpre
92                                              Hyperglycemic clamps were performed in 14 severely obese
93 for hepatic glycogen synthesis and turnover, hyperglycemic clamps were performed with somatostatin [0
94 ulin secretion rates (ISR) measured during a hyperglycemic clamp with either GLP-1 receptor blockade
95 e diet [P-HFF]) underwent a hyperinsulinemic-hyperglycemic clamp with intraportal glucose infusion.
96  a randomized order involving 2-h euglycemic-hyperglycemic clamps with coadministration of: 1) SU (gl
97 ut (Cx36(-/-)) mouse phenotype and performed hyperglycemic clamps with rapid sampling of insulin in C